nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.109	0.167	CbGbCtD
Nadolol—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0985	0.151	CbGbCtD
Nadolol—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0851	0.131	CbGbCtD
Nadolol—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0826	0.127	CbGbCtD
Nadolol—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0747	0.115	CbGbCtD
Nadolol—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0747	0.115	CbGbCtD
Nadolol—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0716	0.11	CbGbCtD
Nadolol—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0554	0.085	CbGbCtD
Nadolol—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.000589	0.00169	CcSEcCtD
Nadolol—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.000588	0.00169	CcSEcCtD
Nadolol—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.000587	0.00169	CcSEcCtD
Nadolol—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000582	0.00168	CcSEcCtD
Nadolol—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.000581	0.00167	CcSEcCtD
Nadolol—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000581	0.00167	CcSEcCtD
Nadolol—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000581	0.00167	CcSEcCtD
Nadolol—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000577	0.00166	CcSEcCtD
Nadolol—Cough—Indinavir—acquired immunodeficiency syndrome	0.000577	0.00166	CcSEcCtD
Nadolol—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000576	0.00166	CcSEcCtD
Nadolol—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000573	0.00165	CcSEcCtD
Nadolol—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000572	0.00165	CcSEcCtD
Nadolol—Pain—Stavudine—acquired immunodeficiency syndrome	0.000571	0.00164	CcSEcCtD
Nadolol—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000571	0.00164	CcSEcCtD
Nadolol—Shock—Zidovudine—acquired immunodeficiency syndrome	0.000571	0.00164	CcSEcCtD
Nadolol—Tinnitus—Saquinavir—acquired immunodeficiency syndrome	0.00057	0.00164	CcSEcCtD
Nadolol—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000567	0.00163	CcSEcCtD
Nadolol—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.000564	0.00162	CcSEcCtD
Nadolol—Chest pain—Indinavir—acquired immunodeficiency syndrome	0.000563	0.00162	CcSEcCtD
Nadolol—Pain—Abacavir—acquired immunodeficiency syndrome	0.000563	0.00162	CcSEcCtD
Nadolol—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.000561	0.00161	CcSEcCtD
Nadolol—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.000561	0.00161	CcSEcCtD
Nadolol—Anorexia—Zidovudine—acquired immunodeficiency syndrome	0.000553	0.00159	CcSEcCtD
Nadolol—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000552	0.00159	CcSEcCtD
Nadolol—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000551	0.00158	CcSEcCtD
Nadolol—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.000549	0.00158	CcSEcCtD
Nadolol—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000547	0.00157	CcSEcCtD
Nadolol—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000545	0.00157	CcSEcCtD
Nadolol—Flatulence—Ritonavir—acquired immunodeficiency syndrome	0.000545	0.00157	CcSEcCtD
Nadolol—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000544	0.00157	CcSEcCtD
Nadolol—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.00054	0.00155	CcSEcCtD
Nadolol—Oedema—Indinavir—acquired immunodeficiency syndrome	0.00054	0.00155	CcSEcCtD
Nadolol—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.00054	0.00155	CcSEcCtD
Nadolol—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000537	0.00154	CcSEcCtD
Nadolol—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.000536	0.00154	CcSEcCtD
Nadolol—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.000532	0.00153	CcSEcCtD
Nadolol—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000532	0.00153	CcSEcCtD
Nadolol—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000532	0.00153	CcSEcCtD
Nadolol—Shock—Indinavir—acquired immunodeficiency syndrome	0.000531	0.00153	CcSEcCtD
Nadolol—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.00053	0.00152	CcSEcCtD
Nadolol—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000528	0.00152	CcSEcCtD
Nadolol—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000526	0.00151	CcSEcCtD
Nadolol—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000526	0.00151	CcSEcCtD
Nadolol—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000525	0.00151	CcSEcCtD
Nadolol—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.000525	0.00151	CcSEcCtD
Nadolol—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000522	0.0015	CcSEcCtD
Nadolol—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000522	0.0015	CcSEcCtD
Nadolol—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000521	0.0015	CcSEcCtD
Nadolol—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000521	0.0015	CcSEcCtD
Nadolol—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00052	0.0015	CcSEcCtD
Nadolol—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.00052	0.0015	CcSEcCtD
Nadolol—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000518	0.00149	CcSEcCtD
Nadolol—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000516	0.00149	CcSEcCtD
Nadolol—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000516	0.00148	CcSEcCtD
Nadolol—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000515	0.00148	CcSEcCtD
Nadolol—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000511	0.00147	CcSEcCtD
Nadolol—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000509	0.00146	CcSEcCtD
Nadolol—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000505	0.00145	CcSEcCtD
Nadolol—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000502	0.00144	CcSEcCtD
Nadolol—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000501	0.00144	CcSEcCtD
Nadolol—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000501	0.00144	CcSEcCtD
Nadolol—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.0005	0.00144	CcSEcCtD
Nadolol—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000498	0.00143	CcSEcCtD
Nadolol—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000496	0.00143	CcSEcCtD
Nadolol—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000496	0.00143	CcSEcCtD
Nadolol—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000496	0.00143	CcSEcCtD
Nadolol—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000496	0.00143	CcSEcCtD
Nadolol—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000493	0.00142	CcSEcCtD
Nadolol—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000489	0.00141	CcSEcCtD
Nadolol—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000489	0.00141	CcSEcCtD
Nadolol—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000488	0.0014	CcSEcCtD
Nadolol—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000488	0.0014	CcSEcCtD
Nadolol—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000486	0.0014	CcSEcCtD
Nadolol—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000486	0.0014	CcSEcCtD
Nadolol—Rash—Didanosine—acquired immunodeficiency syndrome	0.000485	0.0014	CcSEcCtD
Nadolol—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000485	0.00139	CcSEcCtD
Nadolol—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000485	0.00139	CcSEcCtD
Nadolol—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000483	0.00139	CcSEcCtD
Nadolol—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000481	0.00138	CcSEcCtD
Nadolol—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000481	0.00138	CcSEcCtD
Nadolol—Shock—Delavirdine—acquired immunodeficiency syndrome	0.00048	0.00138	CcSEcCtD
Nadolol—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000479	0.00138	CcSEcCtD
Nadolol—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000478	0.00137	CcSEcCtD
Nadolol—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000477	0.00137	CcSEcCtD
Nadolol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000475	0.00137	CcSEcCtD
Nadolol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000474	0.00136	CcSEcCtD
Nadolol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000473	0.00136	CcSEcCtD
Nadolol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000473	0.00136	CcSEcCtD
Nadolol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000472	0.00136	CcSEcCtD
Nadolol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000472	0.00136	CcSEcCtD
Nadolol—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000471	0.00135	CcSEcCtD
Nadolol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000469	0.00135	CcSEcCtD
Nadolol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000468	0.00135	CcSEcCtD
Nadolol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000466	0.00134	CcSEcCtD
Nadolol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000466	0.00134	CcSEcCtD
Nadolol—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000465	0.00134	CcSEcCtD
Nadolol—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000465	0.00134	CcSEcCtD
Nadolol—Pain—Indinavir—acquired immunodeficiency syndrome	0.000462	0.00133	CcSEcCtD
Nadolol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000462	0.00133	CcSEcCtD
Nadolol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000461	0.00133	CcSEcCtD
Nadolol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000461	0.00132	CcSEcCtD
Nadolol—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00046	0.00132	CcSEcCtD
Nadolol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000459	0.00132	CcSEcCtD
Nadolol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000458	0.00132	CcSEcCtD
Nadolol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000458	0.00132	CcSEcCtD
Nadolol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000457	0.00131	CcSEcCtD
Nadolol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000457	0.00131	CcSEcCtD
Nadolol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000456	0.00131	CcSEcCtD
Nadolol—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000455	0.00131	CcSEcCtD
Nadolol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000455	0.00131	CcSEcCtD
Nadolol—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000453	0.0013	CcSEcCtD
Nadolol—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000451	0.0013	CcSEcCtD
Nadolol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00045	0.00129	CcSEcCtD
Nadolol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000449	0.00129	CcSEcCtD
Nadolol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000446	0.00128	CcSEcCtD
Nadolol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000444	0.00128	CcSEcCtD
Nadolol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000443	0.00128	CcSEcCtD
Nadolol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000443	0.00127	CcSEcCtD
Nadolol—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000443	0.00127	CcSEcCtD
Nadolol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000443	0.00127	CcSEcCtD
Nadolol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000442	0.00127	CcSEcCtD
Nadolol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000441	0.00127	CcSEcCtD
Nadolol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00044	0.00127	CcSEcCtD
Nadolol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.00044	0.00126	CcSEcCtD
Nadolol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000438	0.00126	CcSEcCtD
Nadolol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000436	0.00125	CcSEcCtD
Nadolol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000436	0.00125	CcSEcCtD
Nadolol—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000436	0.00125	CcSEcCtD
Nadolol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000436	0.00125	CcSEcCtD
Nadolol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000436	0.00125	CcSEcCtD
Nadolol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000435	0.00125	CcSEcCtD
Nadolol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000435	0.00125	CcSEcCtD
Nadolol—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000434	0.00125	CcSEcCtD
Nadolol—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000432	0.00124	CcSEcCtD
Nadolol—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.00043	0.00124	CcSEcCtD
Nadolol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.00043	0.00124	CcSEcCtD
Nadolol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000427	0.00123	CcSEcCtD
Nadolol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000427	0.00123	CcSEcCtD
Nadolol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000426	0.00123	CcSEcCtD
Nadolol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000425	0.00122	CcSEcCtD
Nadolol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000424	0.00122	CcSEcCtD
Nadolol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000423	0.00122	CcSEcCtD
Nadolol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000422	0.00122	CcSEcCtD
Nadolol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000422	0.00121	CcSEcCtD
Nadolol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000422	0.00121	CcSEcCtD
Nadolol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000421	0.00121	CcSEcCtD
Nadolol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000421	0.00121	CcSEcCtD
Nadolol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000421	0.00121	CcSEcCtD
Nadolol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.00042	0.00121	CcSEcCtD
Nadolol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000418	0.0012	CcSEcCtD
Nadolol—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000417	0.0012	CcSEcCtD
Nadolol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000417	0.0012	CcSEcCtD
Nadolol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000417	0.0012	CcSEcCtD
Nadolol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000415	0.00119	CcSEcCtD
Nadolol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000415	0.00119	CcSEcCtD
Nadolol—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000414	0.00119	CcSEcCtD
Nadolol—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000414	0.00119	CcSEcCtD
Nadolol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000411	0.00118	CcSEcCtD
Nadolol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000411	0.00118	CcSEcCtD
Nadolol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000408	0.00117	CcSEcCtD
Nadolol—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000408	0.00117	CcSEcCtD
Nadolol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000406	0.00117	CcSEcCtD
Nadolol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000405	0.00117	CcSEcCtD
Nadolol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000403	0.00116	CcSEcCtD
Nadolol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000402	0.00116	CcSEcCtD
Nadolol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000401	0.00115	CcSEcCtD
Nadolol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000398	0.00114	CcSEcCtD
Nadolol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000397	0.00114	CcSEcCtD
Nadolol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000397	0.00114	CcSEcCtD
Nadolol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000397	0.00114	CcSEcCtD
Nadolol—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000395	0.00114	CcSEcCtD
Nadolol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000393	0.00113	CcSEcCtD
Nadolol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000392	0.00113	CcSEcCtD
Nadolol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000391	0.00112	CcSEcCtD
Nadolol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00039	0.00112	CcSEcCtD
Nadolol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000389	0.00112	CcSEcCtD
Nadolol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000387	0.00111	CcSEcCtD
Nadolol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000387	0.00111	CcSEcCtD
Nadolol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000387	0.00111	CcSEcCtD
Nadolol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000386	0.00111	CcSEcCtD
Nadolol—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000386	0.00111	CcSEcCtD
Nadolol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000386	0.00111	CcSEcCtD
Nadolol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000384	0.0011	CcSEcCtD
Nadolol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000382	0.0011	CcSEcCtD
Nadolol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000382	0.0011	CcSEcCtD
Nadolol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000378	0.00109	CcSEcCtD
Nadolol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000375	0.00108	CcSEcCtD
Nadolol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000375	0.00108	CcSEcCtD
Nadolol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000372	0.00107	CcSEcCtD
Nadolol—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000372	0.00107	CcSEcCtD
Nadolol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000372	0.00107	CcSEcCtD
Nadolol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00037	0.00106	CcSEcCtD
Nadolol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000369	0.00106	CcSEcCtD
Nadolol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000369	0.00106	CcSEcCtD
Nadolol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000366	0.00105	CcSEcCtD
Nadolol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000366	0.00105	CcSEcCtD
Nadolol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000366	0.00105	CcSEcCtD
Nadolol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000365	0.00105	CcSEcCtD
Nadolol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000361	0.00104	CcSEcCtD
Nadolol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00036	0.00104	CcSEcCtD
Nadolol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000357	0.00103	CcSEcCtD
Nadolol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000357	0.00103	CcSEcCtD
Nadolol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000357	0.00103	CcSEcCtD
Nadolol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000354	0.00102	CcSEcCtD
Nadolol—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000354	0.00102	CcSEcCtD
Nadolol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00035	0.00101	CcSEcCtD
Nadolol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000349	0.001	CcSEcCtD
Nadolol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000345	0.000993	CcSEcCtD
Nadolol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000345	0.000992	CcSEcCtD
Nadolol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000343	0.000988	CcSEcCtD
Nadolol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000343	0.000987	CcSEcCtD
Nadolol—Rash—Indinavir—acquired immunodeficiency syndrome	0.00034	0.000979	CcSEcCtD
Nadolol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00034	0.000978	CcSEcCtD
Nadolol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000337	0.00097	CcSEcCtD
Nadolol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000334	0.000961	CcSEcCtD
Nadolol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000328	0.000942	CcSEcCtD
Nadolol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000324	0.000933	CcSEcCtD
Nadolol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000324	0.000931	CcSEcCtD
Nadolol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000323	0.000928	CcSEcCtD
Nadolol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000322	0.000925	CcSEcCtD
Nadolol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000321	0.000924	CcSEcCtD
Nadolol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000321	0.000922	CcSEcCtD
Nadolol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000319	0.000918	CcSEcCtD
Nadolol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000312	0.000896	CcSEcCtD
Nadolol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00031	0.000893	CcSEcCtD
Nadolol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000309	0.000888	CcSEcCtD
Nadolol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000308	0.000885	CcSEcCtD
Nadolol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000307	0.000884	CcSEcCtD
Nadolol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000307	0.000884	CcSEcCtD
Nadolol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000303	0.000871	CcSEcCtD
Nadolol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000298	0.000858	CcSEcCtD
Nadolol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000297	0.000855	CcSEcCtD
Nadolol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000297	0.000855	CcSEcCtD
Nadolol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000293	0.000843	CcSEcCtD
Nadolol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00029	0.000834	CcSEcCtD
Nadolol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000287	0.000826	CcSEcCtD
Nadolol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000287	0.000825	CcSEcCtD
Nadolol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000285	0.000819	CcSEcCtD
Nadolol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000284	0.000818	CcSEcCtD
Nadolol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000284	0.000816	CcSEcCtD
Nadolol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000276	0.000794	CcSEcCtD
Nadolol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000274	0.000788	CcSEcCtD
Nadolol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000274	0.000788	CcSEcCtD
Nadolol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000274	0.000787	CcSEcCtD
Nadolol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000268	0.000771	CcSEcCtD
Nadolol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.000758	CcSEcCtD
Nadolol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000261	0.000752	CcSEcCtD
Nadolol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000261	0.000751	CcSEcCtD
Nadolol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000258	0.000742	CcSEcCtD
Nadolol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000246	0.000708	CcSEcCtD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	2.71e-05	0.0344	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	2.56e-05	0.0325	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	2.06e-05	0.0262	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	1.64e-05	0.0209	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	1.61e-05	0.0204	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	1.57e-05	0.02	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	1.49e-05	0.0189	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	1.25e-05	0.0159	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	1.23e-05	0.0156	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	1.2e-05	0.0152	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	1.13e-05	0.0144	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	1.07e-05	0.0136	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	1.06e-05	0.0135	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	1.01e-05	0.0129	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	1.01e-05	0.0128	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	9.75e-06	0.0124	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	9.54e-06	0.0121	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	9.25e-06	0.0117	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	9.25e-06	0.0117	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	9.22e-06	0.0117	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.18e-06	0.0117	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	8.82e-06	0.0112	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.63e-06	0.011	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.63e-06	0.011	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	8.62e-06	0.011	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	8.01e-06	0.0102	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.73e-06	0.00981	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	7.42e-06	0.00943	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	7.26e-06	0.00922	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.99e-06	0.00888	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.9e-06	0.00877	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	6.71e-06	0.00853	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.57e-06	0.00835	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.57e-06	0.00835	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	6.57e-06	0.00834	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.56e-06	0.00834	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.42e-06	0.00815	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	6.36e-06	0.00808	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	6.29e-06	0.00799	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.26e-06	0.00795	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	6.22e-06	0.0079	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	6.15e-06	0.00781	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	6.07e-06	0.00771	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	6.07e-06	0.00771	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	6.02e-06	0.00765	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	5.98e-06	0.00759	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.91e-06	0.00751	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	5.9e-06	0.0075	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	5.89e-06	0.00748	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	5.85e-06	0.00743	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.81e-06	0.00737	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	5.77e-06	0.00733	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	5.45e-06	0.00692	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	5.33e-06	0.00677	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	5.12e-06	0.0065	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	5.12e-06	0.0065	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	5.01e-06	0.00636	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	5.01e-06	0.00636	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5e-06	0.00635	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	4.59e-06	0.00583	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.5e-06	0.00572	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	4.49e-06	0.0057	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.15e-06	0.00527	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.1e-06	0.0052	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.06e-06	0.00515	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.01e-06	0.00509	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.97e-06	0.00504	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.95e-06	0.00502	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.9e-06	0.00495	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.9e-06	0.00495	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.9e-06	0.00495	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.82e-06	0.00485	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.82e-06	0.00485	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.81e-06	0.00484	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.81e-06	0.00484	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.79e-06	0.00482	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.79e-06	0.00482	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.73e-06	0.00473	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.71e-06	0.00472	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.71e-06	0.00472	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.71e-06	0.00472	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.63e-06	0.00462	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.59e-06	0.00456	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	3.57e-06	0.00453	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.51e-06	0.00446	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.45e-06	0.00438	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.43e-06	0.00436	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.43e-06	0.00436	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.37e-06	0.00428	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.37e-06	0.00428	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.37e-06	0.00428	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	3.17e-06	0.00403	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.97e-06	0.00377	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.9e-06	0.00369	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.82e-06	0.00359	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.78e-06	0.00353	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.67e-06	0.00339	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.61e-06	0.00332	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.57e-06	0.00326	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.54e-06	0.00323	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.53e-06	0.00321	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.35e-06	0.00299	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.34e-06	0.00298	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.34e-06	0.00298	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.31e-06	0.00294	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.31e-06	0.00293	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.3e-06	0.00292	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.29e-06	0.00291	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.25e-06	0.00286	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.25e-06	0.00286	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.2e-06	0.0028	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.2e-06	0.0028	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.2e-06	0.0028	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.2e-06	0.0028	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.16e-06	0.00274	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.16e-06	0.00274	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.13e-06	0.0027	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.12e-06	0.00269	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.08e-06	0.00264	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.06e-06	0.00261	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.04e-06	0.00259	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2e-06	0.00254	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2e-06	0.00254	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.99e-06	0.00253	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.99e-06	0.00253	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.99e-06	0.00253	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.96e-06	0.00249	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.96e-06	0.00249	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.75e-06	0.00222	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.68e-06	0.00213	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.65e-06	0.0021	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.64e-06	0.00208	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.62e-06	0.00205	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.52e-06	0.00193	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.52e-06	0.00192	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.51e-06	0.00192	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.5e-06	0.0019	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.49e-06	0.0019	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.49e-06	0.00189	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.48e-06	0.00188	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.47e-06	0.00187	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.47e-06	0.00186	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.39e-06	0.00177	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.37e-06	0.00174	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.37e-06	0.00173	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.36e-06	0.00173	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.34e-06	0.0017	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.34e-06	0.0017	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.26e-06	0.0016	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.23e-06	0.00156	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.18e-06	0.0015	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.18e-06	0.0015	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.16e-06	0.00147	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.16e-06	0.00147	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.14e-06	0.00145	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.99e-07	0.00114	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.86e-07	0.00113	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.8e-07	0.00112	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.73e-07	0.00111	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.67e-07	0.0011	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	8.54e-07	0.00108	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.1e-07	0.00103	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.93e-07	0.00101	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.93e-07	0.00101	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.89e-07	0.001	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.85e-07	0.000997	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	7.75e-07	0.000985	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.66e-07	0.000973	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.68e-07	0.000595	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.66e-07	0.000592	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.64e-07	0.000589	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.58e-07	0.000582	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.56e-07	0.000579	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	3.59e-07	0.000456	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.75e-07	0.00035	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.69e-07	0.000342	CbGpPWpGaD
